Equities

Merck & Co Inc

0QAH:LSE

Merck & Co Inc

  • Price (USD)122.24
  • Today's Change2.10 / 1.75%
  • Shares traded18.95k
  • 1 Year change38.05%
  • Beta0.2782
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

  • Revenue in USD (TTM)65.01bn
  • Net income in USD18.25bn
  • Incorporated1970
  • Employees75.00k
  • Location
    Merck & Co Inc126 East Lincoln Avenue,P.O. Box 2000RAHWAY 07065United StatesUSA
  • Phone+1 (908) 740-4000Fax+1 (908) 423-1987
  • Websitehttps://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QAH:LSE since
announced		Transaction
value
Revolution Medicines IncPrior rumour discounted08 Jan 202608 Jan 2026Prior rumour discounted12.56%--
MoonLake ImmunotherapeuticsRumoured02 Jun 202502 Jun 2025Rumoured59.08%--
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.